البحث الشامل غير مفعل
تخطى إلى المحتوى الرئيسي
كتاب

steroid‑resistant nephrotic syndrome (SRNS)

متطلبات الإكمال
"last update: 17 September 2026"                                                                           Download Guideline

- Annexes

Annex Table 1.

Declaration of Conflict of Interests

The members of the guideline development/ adaptation group and the external review group have no academic, financial, or competing interests to declare and none of them were involved in the development of the original source guideline(s).

Any identified potential COI has been reported below.

Egyptian Pediatric Clinical Practice Guidelines Committee (EPG)

Guideline Adaptation Group (Clinical subgroup)

Name

Affiliation, Area of expertise / Role, Country / Primary location [work]

Declaration of interests

Interest

identified

Management plan & decision

Bahia Moustafa

Professor of Pediatrics & Pediatric Nephrology, Cairo University,

Egypt

None

Not Applicable

Sawsan Moselhy

Department of Pediatric, Pediatric Nephrology Division, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

None

Not Applicable

Moftah Rabie

Department

of Pediatric, Pediatric Nephrology Division, Faculty of Medicine, Azhar

University, Cairo, Egypt.

None

Not Applicable

Ayman Hammad

Department of Pediatric, Pediatric Nephrology

Division, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

None

Not Applicable

Doaa Youssef

Department

of Pediatric, Pediatric Nephrology Division, Faculty of Medicine, Zagazig

University, Zagazig, Egypt.

None

Not Applicable

Mohamed Shouman

Department of Pediatric, Medical Research

and Clinical Studies Institute, National Research Centre, Cairo, Egypt.

None

Not Applicable

Samuel Makar

Department of Pediatric, Pediatric Nephrology Division, Faculty of Medicine,

Cairo University, Cairo, Egypt

None

Not Applicable

Ahmed Badr

Department of Pediatric, Pediatric Nephrology Division, Faculty of Medicine,

Cairo University, Cairo, Egypt

None

Not Applicable

Sameh Mansour

Department

of Pediatric, Pediatric Nephrology Division, Faculty of Medicine, Azhar

University, Cairo, Egypt.

None

Not Applicable

Dina Ebrahim

Department of Pediatric, Pediatric Nephrology

Division, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

None

Not Applicable

Marwa Nabhan

Department of Pediatric, Pediatric Nephrology Division, Faculty of Medicine,

Cairo University, Cairo, Egypt

None

Not Applicable

Fatma Ateia

Department of Pediatric, Pediatric Nephrology Division, Faculty of Medicine,

Cairo University, Cairo, Egypt

None

Not Applicable

Hend Abdel‑Nabi

Department

of Pediatric, Pediatric Nephrology Division, Faculty of Medicine, Tanta

University, Tanta, Egypt.

None

Not Applicable

Ahmed Hussein

Department of Pediatric, Pediatric Nephrology

Division, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

None

Not Applicable

Manal Salman

Department of Pathology, Faculty of Medicine, Ain

Shams University, Cairo, Egypt.

None

Not Applicable

Mai S. Korkor

Department of Pediatric, Pediatric Nephrology

Division, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

None

Not Applicable

Esraa A. Elbahkiry

Clinical Pharmacist, Faculty of Medicine,

Mansoura University, Mansoura, Egypt.

None

Not Applicable

Marwa Dagher

Clinical Pharmacist, Faculty of Medicine,

Mansoura University, Mansoura, Egypt.

None

Not Applicable

Abeer Selim

Department of Pediatric, Medical Research

and Clinical Studies Institute, National Research Centre, Cairo, Egypt.

None

Not Applicable

Guideline Adaptation Group (Methodology Subgroup)

Prof. Ashraf Abdel Baky

Professor of Pediatrics

Ain Shams University, Egypt

Founder and Chair of EPG

None

Not Applicable

Dr. Yasser Sami Amer

1. Pediatrics Department and Clinical Practice Guidelines and Quality Research Unit, Quality Management Department, King Saud University Medical City, Riyadh, Saudi Arabia;

2. Research Chair for Evidence-Based Health Care and Knowledge Translation, King Saud University, Riyadh, Saudi Arabia;

3. Chair, Adaptation Working Group, Guidelines International Network (GIN), Perth, Scotland

4. Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil.

None

Not Applicable

Tarek El-Sayed Ismail Omar

Professor of Pediatrics and Pediatric Neurology

Alexandria Center for Evidence‑Based

Clinical Practice Guidelines

Faculty of Medicine Alexandria University, Egypt.

None

Not Applicable

Dr. Lamis Mohsen Elsholkamy

Lecturer of Pediatrics, Faculty of Medicine, Modern University for Technology and Information (MTI), Egypt

None

Not Applicable

External Review Group

Amr Sarhan

Pediatric Nephrology Mansoura University

 

None

Not Applicable

Neveen A Soliman

Pediatric Nephrology Cairo University

None

Not Applicable

Ihab El Hakim

Pediatric Nephrology Ain Shams University

None

Not Applicable

External Reviewer for methodology

Prof. Iván D. Flórez

Department of Pediatrics, University of Antioquia, Medellín, Colombia,

Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada,

Leader, AGREE Collaboration (Appraisal of Guidelines for Research & Evaluation)

Director, Cochrane Colombia

None

Not Applicable

International Peer Reviewers

 

 

Federica Zotta

Division of Nephrology, Department of Pediatric subspecialities. Bambino Gesu Children Hospital (IRCCS), Rome, Italy.

None

Not Applicable


➡️Web annexes

The following annexes can be added as a package of standalone supplementary documents.

Keywords: The MeSH terms for "Guideline for the steroid‑resistant nephrotic syndrome " on PubMed are: : Steroid-resistant nephrotic syndrome, Diagnosis, Treatment, Follow up, Pediatric guidelines.


Annex Table 2. Results of the AGREE II assessment of

A-     IPNA clinical practice recommendations for the diagnosis and management of children

 with steroid-resistant nephrotic syndrome

b-         Evidence-Based Clinical Practice Guidelines for Nephrotic Syndrome JSPN 2014,

c-         KDIGO Clinical Practice Guideline on Glomerular Diseases, using the AGREE II Instrument. 

Appendix Table 4. The RIGHT-Ad@pt checklist

7 sections, 27 topics, and 34 items

Assessment

Page(s)*

Note(s)

BASIC INFORMATION

Title/subtitle

1

Identify the report as an adaptation of practice guideline(s), that is include "guideline adaptation", "adapting", "adapted guideline/recommendation(s)", or similar terminology in the title/subtitle.

Yes

No

Unclear

 

 

2

Describe the topic/focus/scope of the adapted guideline.

Yes

No

Unclear

 

 

Cover/first page

3

Report the respective dates of publication and the literature search of the adapted guideline.

Yes

No

Unclear

 

 

4

Describe the developer and country/region of the adapted guideline.

Yes

No

Unclear

 

 

Executive summary/abstract

5

Provide a summary of the recommendations contained in the adapted guideline.

Yes

No

Unclear

 

 

Abbreviations and acronyms

6

Define key terms and provide a list of abbreviations and acronyms (if applicable).

Yes

No

Unclear

 

 

Contact information of the guideline adaptation group

7

Report the contact information of the developer of the adapted guideline.

Yes

No

Unclear

 

 

SCOPE

Source guideline(s)

8

Report the name and year of publication of the source guideline(s), provide the citation(s), and whether source authors were contacted.

Yes

No

Unclear

 

 

Brief description of the health problem(s)

9

Provide the basic epidemiological information about the problem (including the associated burden), health systems relevant issues, and note any relevant differences compared to the source guideline(s).

 

Yes

No

Unclear

 

 

Aim(s) and specific objectives

10

Describe the aim(s) of the adapted guideline and specific objectives, and note any relevant differences compared to the source guideline(s).

Yes

No

Unclear

 

 

Target population(s)

11

Describe the target population(s) and subgroup(s) (if applicable) to which the recommendation(s) is addressed in the adapted guideline, and note any relevant differences compared to the source guideline(s).

Yes

No

Unclear

 

 

End-users and settings

12

Describe the intended target users of the adapted guideline, and note any relevant differences compared to the source guideline(s).

Yes

No

Unclear

 

 

13

Describe the setting(s) for which the adapted guideline is intended, and note any relevant differences compared to the source guideline(s).

Yes

No

Unclear

 

 

RIGOR OF DEVELOPMENT

Guideline adaptation group

14

List all contributors to the guideline adaptation process and describe their selection process and responsibilities.

Yes

No

Unclear

 

 

Adaptation framework/methodology

15

Report which framework or methodology was used in the guideline adaptation process.

Yes

No

Unclear

 

 

Source guideline(s)

16

Describe how the specific source guideline(s) was(were) selected.

Yes

No

Unclear

 

 

Key questions

17

State the key questions of the adapted guideline using a structured format, such as PICO (population, intervention, comparator, and outcome), or another format as appropriate.

Yes

No

Unclear

 

 

18

Describe how the key questions were developed/modified, and/or prioritized.

Yes

No

Unclear

 

 

Source recommendation(s)

19

Describe how the recommendation(s) from the source guideline(s) was(were) assessed with respect to the evidence considered for the different criteria, the judgements and considerations made by the original panel.

Yes

No

Unclear

 

 

Evidence synthesis

20

Indicate whether the adapted recommendation(s) is/are based on existing evidence from the source guideline(s), and/or additional evidence.

Yes

No

Unclear

 

 

21

If new research evidence was used, describe how it was identified and assessed.

Yes

No

Unclear

NA

 

Assessment of the certainty of the body of evidence and strength of recommendation

22

Describe the approach used to assess the certainty/quality of the body/ies of evidence and the strength of recommendations in the adapted guideline and note any differences (if applicable) compared to the source guideline(s).

Yes

No

Unclear

NA

 

Decision-making processes

23

Describe the processes used by the guideline adaptation group to make decisions, particularly the formulation of recommendations.

 

Yes

No

Unclear

 

 

RECOMMENDATIONS

Recommendations

24

Report recommendations and indicate whether they were adapted, adopted, or de novo.

Yes

No

Unclear

 

 

25

Indicate the direction and strength of the recommendations and the certainty/quality of the supporting evidence and note any differences compared to the source recommendations(s) (if applicable).

Yes

No

Unclear

 

 

26

Present separate recommendations for important subgroups if the evidence suggests important differences in factors influencing recommendations and note any differences compared to the source recommendations(s) (If applicable).

Yes

No

Unclear

 

 

Rationale/explanation for recommendations

27

Describe the criteria/factors that were considered to formulate the recommendations or note any relevant differences compared to the source guideline(s) (if applicable).

Yes

No

Unclear

 

 

EXTERNAL REVIEW AND QUALITY ASSURANCE

External review

28

Indicate whether the adapted guideline underwent an independent external review. If yes, describe the process.

Yes

No

Unclear

 

 

Organizational approval

29

Indicate whether the adapted guideline obtained organizational approval. If yes, describe the process.

Yes

No

Unclear

SNS  & NEBMC

 

FUNDING, DECLARATION, AND MANAGEMENT OF INTEREST

Funding source(s) and funder role(s)

30

Report all sources of funding for the adapted guideline and source guideline(s), and the role of the funders.

Yes

No

Unclear

 

 

Declaration and management of interests

31

Report all conflicts of interest of the adapted and the source guideline(s) panels, and how they were evaluated and managed.

Yes

No

Unclear

 

 

OTHER INFORMATION

Implementation

32

Describe the potential barriers and strategies for implementing the recommendations (if applicable).

Yes

No

Unclear

 

 

Update

33

Briefly describe the strategy for updating the adapted guideline (if applicable).

Yes

No

Unclear

 

 

Limitations and suggestions for further research

34

Describe the challenges of the adaptation process, the limitations of the evidence, and provide suggestions for future research.

Yes

No

Unclear

--